39.35
2.97 (8.16%)
| Previous Close | 36.38 |
| Open | 36.46 |
| Volume | 418,305 |
| Avg. Volume (3M) | 384,492 |
| Market Cap | 1,836,737,792 |
| Price / Sales | 17.37 |
| Price / Book | 4.64 |
| 52 Weeks Range | |
| Earnings Date | 9 Nov 2026 |
| Operating Margin (TTM) | -11,831.05% |
| Diluted EPS (TTM) | -1.78 |
| Quarterly Revenue Growth (YOY) | -30.90% |
| Total Debt/Equity (MRQ) | 6.25% |
| Current Ratio (MRQ) | 32.19 |
| Operating Cash Flow (TTM) | -74.10 M |
| Levered Free Cash Flow (TTM) | -25.69 M |
| Return on Assets (TTM) | -17.20% |
| Return on Equity (TTM) | -30.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Septerna, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | -0.33 |
Select this tab to load the latest available analysis.
|
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.64% |
| % Held by Institutions | 105.46% |
No data within this time range.
No data within this time range.
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |